Editas Medicine, Inc.

NASDAQ:EDIT

Biotechnology

Healthcare
$1.77 +2.65%

+$0.07 today

Market cap
$273.18M
Beta
2.10
P/E (TTM)
-2.4
EPS (TTM)
-$1.11
52W Low $1.66High $4.54

Volume 1.99M

Average 2.06M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$165.24M

FY 2025 · Annual

Investing Cash Flow

$138.67M

FY 2025 · Annual

-14.5% YoY

Financing Cash Flow

$40.47M

FY 2025 · Annual

-27.8% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(192.5M)(220.43M)(153.22M)(237.09M)(160.06M)
Depreciation & Amortization5.05M6.34M6.06M5.81M5.28M
Deferred Income Tax00000
Stock-Based Compensation43.4M29.29M19.8M21.42M10M
Change in Working Capital(21.41M)8.18M(1.59M)3.45M(31.23M)
Accounts Receivables5.78M(4.88M)(5.04M)(6.08M)1.09M
Inventory(3.35M)0000
Accounts Payables(1.14M)4.37M(1.49M)(2.29M)(2.89M)
Other Working Capital(22.71M)8.69M4.94M11.82M(29.43M)
Other Non-Cash Items1.66M(724K)(3.23M)(3.87M)10.77M
Operating Cash Flow(163.8M)(177.35M)(132.18M)(210.28M)(165.24M)
Capital Expenditures(7.98M)(4.12M)(4.72M)(8.83M)(607K)
Acquisitions (Net)46.49M18K00269K
Purchases of Investments(408.89M)(315.19M)(258.52M)(86.22M)0
Sales of Investments362.4M433.35M259.51M257.19M139.01M
Other Investing Activities(46.49M)0000
Investing Cash Flow(54.47M)114.07M(3.73M)162.15M138.67M
Debt Repayment0000(2.87M)
Common Stock Issued249.46M1.28M117.08M56.03M43.34M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities32.65M0960K00
Financing Cash Flow282.11M1.28M118.04M56.03M40.47M
Effect of Forex Changes00000
Net Change in Cash63.84M(62M)(17.87M)7.89M13.9M
Free Cash Flow(171.78M)(181.47M)(136.9M)(219.11M)(165.85M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$160.1M
+ D&A$5.3M
+ Stock-Based Comp$10.0M
+ Deferred Tax$0
- Working Capital-$31.2M
+ Other Non-Cash$10.8M
= Operating Cash Flow-$165.2M
- Capex-$607.0K
= Free Cash Flow-$165.8M

Analysis

FY2025 free cash flow is -$165.8M. FCF conversion is 103.6% of net income. Operating cash flow was -$165.2M, with capex of -$607.0K. The largest bridge item is Working Capital at -$31.2M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 13, 2026
4Statement of changes in beneficial ownershipNov 13, 2026
10-QQuarterly reportNov 9, 2026
8-KCurrent reportNov 9, 2026
4Statement of changes in beneficial ownershipNov 6, 2026

Does EDIT generate free cash flow?

Editas Medicine, Inc. (EDIT) generated -$165.85M of free cash flow in fiscal 2025.

How much operating cash flow does EDIT produce?

Operating cash flow was -$165.24M, before capital expenditures of $607,000.00.